Eintrag weiter verarbeiten
Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia
Gespeichert in:
| Zeitschriftentitel: | Medical Principles and Practice |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Medical Principles and Practice, 23, 2014, 2, S. 99-111 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
S. Karger AG
|
| Schlagwörter: |
| author_facet |
Elshourbagy, Nabil A. Meyers, Harold V. Abdel-Meguid, Sherin S. Elshourbagy, Nabil A. Meyers, Harold V. Abdel-Meguid, Sherin S. |
|---|---|
| author |
Elshourbagy, Nabil A. Meyers, Harold V. Abdel-Meguid, Sherin S. |
| spellingShingle |
Elshourbagy, Nabil A. Meyers, Harold V. Abdel-Meguid, Sherin S. Medical Principles and Practice Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia General Medicine |
| author_sort |
elshourbagy, nabil a. |
| spelling |
Elshourbagy, Nabil A. Meyers, Harold V. Abdel-Meguid, Sherin S. 1011-7571 1423-0151 S. Karger AG General Medicine http://dx.doi.org/10.1159/000356856 <jats:p>Maintaining cholesterol and triglyceride (TG) levels within healthy limits is critical for decreasing the risk of heart disease. Dyslipidemia refers to the abnormal levels of lipids in the blood, including low high-density lipoprotein cholesterol (HDL-C), also known as good cholesterol, high low-density lipoprotein cholesterol (LDL-C), also known as bad cholesterol, and/or high TG levels that contribute to the development and progression of atherosclerosis. In this article we reviewed some of the current therapeutic targets for the treatment of dyslipidemia, with a primary focus on endothelial lipase and lecithin cholesterol acyl transferase for raising HDL-C, and the proprotein convertase subtilisin-like kexin type 9 (PCSK9), microsomal triglyceride transfer protein, and the messenger RNA of apolipoprotein B for lowering LDL-C. In addition, we reviewed the role of apolipoprotein AI (apoAI) in raising HDL-C, where we discuss three apoAI-based drugs under development. These are its mutated dimer (apoAI-Milano), a complex with phospholipids, and a mimetic peptide. Atherosclerosis, mainly because of dyslipidemia, is a leading cause of cardiovascular disease. Regarding the title of this article, the ‘good' refers to HDL-C, the ‘bad' refers to LDL-C, and the ‘ugly' refers to atherosclerosis.</jats:p> Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia Medical Principles and Practice |
| doi_str_mv |
10.1159/000356856 |
| facet_avail |
Online Free |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDAzNTY4NTY |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDAzNTY4NTY |
| institution |
DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 |
| imprint |
S. Karger AG, 2014 |
| imprint_str_mv |
S. Karger AG, 2014 |
| issn |
1011-7571 1423-0151 |
| issn_str_mv |
1011-7571 1423-0151 |
| language |
English |
| mega_collection |
S. Karger AG (CrossRef) |
| match_str |
elshourbagy2014cholesterolthegoodthebadandtheuglytherapeutictargetsforthetreatmentofdyslipidemia |
| publishDateSort |
2014 |
| publisher |
S. Karger AG |
| recordtype |
ai |
| record_format |
ai |
| series |
Medical Principles and Practice |
| source_id |
49 |
| title |
Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| title_unstemmed |
Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| title_full |
Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| title_fullStr |
Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| title_full_unstemmed |
Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| title_short |
Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| title_sort |
cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia |
| topic |
General Medicine |
| url |
http://dx.doi.org/10.1159/000356856 |
| publishDate |
2014 |
| physical |
99-111 |
| description |
<jats:p>Maintaining cholesterol and triglyceride (TG) levels within healthy limits is critical for decreasing the risk of heart disease. Dyslipidemia refers to the abnormal levels of lipids in the blood, including low high-density lipoprotein cholesterol (HDL-C), also known as good cholesterol, high low-density lipoprotein cholesterol (LDL-C), also known as bad cholesterol, and/or high TG levels that contribute to the development and progression of atherosclerosis. In this article we reviewed some of the current therapeutic targets for the treatment of dyslipidemia, with a primary focus on endothelial lipase and lecithin cholesterol acyl transferase for raising HDL-C, and the proprotein convertase subtilisin-like kexin type 9 (PCSK9), microsomal triglyceride transfer protein, and the messenger RNA of apolipoprotein B for lowering LDL-C. In addition, we reviewed the role of apolipoprotein AI (apoAI) in raising HDL-C, where we discuss three apoAI-based drugs under development. These are its mutated dimer (apoAI-Milano), a complex with phospholipids, and a mimetic peptide. Atherosclerosis, mainly because of dyslipidemia, is a leading cause of cardiovascular disease. Regarding the title of this article, the ‘good' refers to HDL-C, the ‘bad' refers to LDL-C, and the ‘ugly' refers to atherosclerosis.</jats:p> |
| container_issue |
2 |
| container_start_page |
99 |
| container_title |
Medical Principles and Practice |
| container_volume |
23 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346203071971337 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:35:39.968Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Cholesterol%3A+The+Good%2C+the+Bad%2C+and+the+Ugly+-+Therapeutic+Targets+for+the+Treatment+of+Dyslipidemia&rft.date=2014-01-01&genre=article&issn=1423-0151&volume=23&issue=2&spage=99&epage=111&pages=99-111&jtitle=Medical+Principles+and+Practice&atitle=Cholesterol%3A+The+Good%2C+the+Bad%2C+and+the+Ugly+-+Therapeutic+Targets+for+the+Treatment+of+Dyslipidemia&aulast=Abdel-Meguid&aufirst=Sherin+S.&rft_id=info%3Adoi%2F10.1159%2F000356856&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346203071971337 |
| author | Elshourbagy, Nabil A., Meyers, Harold V., Abdel-Meguid, Sherin S. |
| author_facet | Elshourbagy, Nabil A., Meyers, Harold V., Abdel-Meguid, Sherin S., Elshourbagy, Nabil A., Meyers, Harold V., Abdel-Meguid, Sherin S. |
| author_sort | elshourbagy, nabil a. |
| container_issue | 2 |
| container_start_page | 99 |
| container_title | Medical Principles and Practice |
| container_volume | 23 |
| description | <jats:p>Maintaining cholesterol and triglyceride (TG) levels within healthy limits is critical for decreasing the risk of heart disease. Dyslipidemia refers to the abnormal levels of lipids in the blood, including low high-density lipoprotein cholesterol (HDL-C), also known as good cholesterol, high low-density lipoprotein cholesterol (LDL-C), also known as bad cholesterol, and/or high TG levels that contribute to the development and progression of atherosclerosis. In this article we reviewed some of the current therapeutic targets for the treatment of dyslipidemia, with a primary focus on endothelial lipase and lecithin cholesterol acyl transferase for raising HDL-C, and the proprotein convertase subtilisin-like kexin type 9 (PCSK9), microsomal triglyceride transfer protein, and the messenger RNA of apolipoprotein B for lowering LDL-C. In addition, we reviewed the role of apolipoprotein AI (apoAI) in raising HDL-C, where we discuss three apoAI-based drugs under development. These are its mutated dimer (apoAI-Milano), a complex with phospholipids, and a mimetic peptide. Atherosclerosis, mainly because of dyslipidemia, is a leading cause of cardiovascular disease. Regarding the title of this article, the ‘good' refers to HDL-C, the ‘bad' refers to LDL-C, and the ‘ugly' refers to atherosclerosis.</jats:p> |
| doi_str_mv | 10.1159/000356856 |
| facet_avail | Online, Free |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDAzNTY4NTY |
| imprint | S. Karger AG, 2014 |
| imprint_str_mv | S. Karger AG, 2014 |
| institution | DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14 |
| issn | 1011-7571, 1423-0151 |
| issn_str_mv | 1011-7571, 1423-0151 |
| language | English |
| last_indexed | 2024-03-01T17:35:39.968Z |
| match_str | elshourbagy2014cholesterolthegoodthebadandtheuglytherapeutictargetsforthetreatmentofdyslipidemia |
| mega_collection | S. Karger AG (CrossRef) |
| physical | 99-111 |
| publishDate | 2014 |
| publishDateSort | 2014 |
| publisher | S. Karger AG |
| record_format | ai |
| recordtype | ai |
| series | Medical Principles and Practice |
| source_id | 49 |
| spelling | Elshourbagy, Nabil A. Meyers, Harold V. Abdel-Meguid, Sherin S. 1011-7571 1423-0151 S. Karger AG General Medicine http://dx.doi.org/10.1159/000356856 <jats:p>Maintaining cholesterol and triglyceride (TG) levels within healthy limits is critical for decreasing the risk of heart disease. Dyslipidemia refers to the abnormal levels of lipids in the blood, including low high-density lipoprotein cholesterol (HDL-C), also known as good cholesterol, high low-density lipoprotein cholesterol (LDL-C), also known as bad cholesterol, and/or high TG levels that contribute to the development and progression of atherosclerosis. In this article we reviewed some of the current therapeutic targets for the treatment of dyslipidemia, with a primary focus on endothelial lipase and lecithin cholesterol acyl transferase for raising HDL-C, and the proprotein convertase subtilisin-like kexin type 9 (PCSK9), microsomal triglyceride transfer protein, and the messenger RNA of apolipoprotein B for lowering LDL-C. In addition, we reviewed the role of apolipoprotein AI (apoAI) in raising HDL-C, where we discuss three apoAI-based drugs under development. These are its mutated dimer (apoAI-Milano), a complex with phospholipids, and a mimetic peptide. Atherosclerosis, mainly because of dyslipidemia, is a leading cause of cardiovascular disease. Regarding the title of this article, the ‘good' refers to HDL-C, the ‘bad' refers to LDL-C, and the ‘ugly' refers to atherosclerosis.</jats:p> Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia Medical Principles and Practice |
| spellingShingle | Elshourbagy, Nabil A., Meyers, Harold V., Abdel-Meguid, Sherin S., Medical Principles and Practice, Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia, General Medicine |
| title | Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| title_full | Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| title_fullStr | Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| title_full_unstemmed | Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| title_short | Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| title_sort | cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia |
| title_unstemmed | Cholesterol: The Good, the Bad, and the Ugly - Therapeutic Targets for the Treatment of Dyslipidemia |
| topic | General Medicine |
| url | http://dx.doi.org/10.1159/000356856 |